Skip to content

Study · Non-randomized trial · 2021

4 results

[Possibilities of neurotrophic therapy for delayed speech development].

Balakireva EA, Klestova EO, Ikonnikov AA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2021Cited by 1 (Europe PMC)

PMID34037354 (opens in a new tab)DOI10.17116/jnevro202112104144 (opens in a new tab)PepBankPUB-34037354
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with delayed speech development, cortexin monotherapy improved speech development.

    In plain wordsIn children with delayed speech development, cortexin monotherapy improved speech development.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseSpeech development
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cortexin in monotherapy in the treatment of delayed speech development is justified not only by its effectiveness in improving speech development and good tolerance
    1 context sentence
    Summary · context
    The article provides an analysis of the possibility of neurotrophic therapy of delayed speech development (DSD) in 266 children who underwent dynamic clinical, laboratory, functional and neuropsychological examinations and received neurotrophic therapy.
  2. 02HumanNon-randomized trialSafety outcome

    In children with delayed speech development, cortexin monotherapy had good tolerance.

    In plain wordsIn children with delayed speech development, cortexin monotherapy had good tolerance.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableTolerance
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The use of cortexin in monotherapy in the treatment of delayed speech development is justified not only by its effectiveness in improving speech development and good tolerance
    1 context sentence
    Summary · context
    The article provides an analysis of the possibility of neurotrophic therapy of delayed speech development (DSD) in 266 children who underwent dynamic clinical, laboratory, functional and neuropsychological examinations and received neurotrophic therapy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with delayed speech development, cortexin monotherapy was associated with improved behavior.

    In plain wordsIn children with delayed speech development, cortexin monotherapy was associated with improved behavior.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseBehavior
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but also in connection with an improvement in behavior in children of the studied groups
    1 context sentence
    Summary · context
    The article provides an analysis of the possibility of neurotrophic therapy of delayed speech development (DSD) in 266 children who underwent dynamic clinical, laboratory, functional and neuropsychological examinations and received neurotrophic therapy.

Studies that did not test the peptide alone1

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

  1. 04HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome

    In children with speech disorder within general psychomotor developmental delay, neuroprotective therapy showed no effect in every sixth child.

    In plain wordsIn children with speech disorder and general developmental delay, treatment showed no effect in every sixth child.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableLack of treatment effect in psychomotor developmental delay
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The lack of effect in the use of neuroprotective therapy in every sixth child of the latter group can be a marker for the individualization of the treatment of each individual with an emphasis on non-drug rehabilitation methods.
    2 context sentences
    Summary · context
    The article provides an analysis of the possibility of neurotrophic therapy of delayed speech development (DSD) in 266 children who underwent dynamic clinical, laboratory, functional and neuropsychological examinations and received neurotrophic therapy.
    Summary · context
    The use of cortexin in monotherapy in the treatment of delayed speech development is justified not only by its effectiveness in improving speech development and good tolerance, but also in connection with an improvement in behavior in children of the studied groups, which is possibly associated with…

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.